生物製藥 CDMO 的全球市場增長機會

本報告對全球生物製藥CDMO市場進行調研分析，涵蓋北美、歐洲、亞太三大區域，對2023年至2028年六年的市場收入進行預測，並進行詳細的細分市場分析。

內容

戰略要務

• 為什麼越來越難成長？
• 戰略要務 8 (TM)
• 三大戰略要務對全球生物製藥 CDMO 行業的影響
• 增長機會推動增長 Pipeline Engine(TM)

增長機會分析

• 分析範圍
• 按產品類型進行市場細分
• 按細胞表達系統類型細分市場
• 按服務類型進行市場細分
• 生物製藥 CDMO 市場的主要區域競爭對手
• 增長動力
• 抑制增長的因素

成長環境-生物製藥CDMO市場

• 生物製藥管線概覽
• 生物製藥 CDMO 商業模式 - 價值鏈擴展
• 概述主要 CDMO 活動以支持促進精準醫療的下一代生物製藥模式
• 生物仿製藥上市對 CDMO 的影響
• 生物製藥 CDMO 行業的主要新趨勢
• 為新進入者鋪平道路的新模式
• 已上市生物製藥的產品分佈（2022 年）
• 生物工藝技術分佈 - 用於哺乳動物製造的一次性生物反應器 (SUB) 和固定床多用途生物反應器 (MUB)
• 生物製造能力的區域分佈

增長機會分析 - 生物製藥 CDMO 行業

• 全球生物製藥 CDMO 市場的主要增長指標
• 預測框架 - 生物製藥 CDMO 的市場規模
• 預測方法 - 生物製藥 CDMO 市場
• 預測假設和考慮因素 - 生物製藥 CDMO 市場
• 收入預測 - 全球生物製藥 CDMO 市場
• 收入預測分析 - 全球生物製藥 CDMO 市場
• 按產品類型預測收入
• 收入預測分析：按產品類型
• 按細胞表達系統類型劃分的收入預測
• 哺乳動物表達系統的利潤預測分析
• 微生物表達系統盈利預測分析
• 其他表達系統的收入預測分析
• 收入分配：按服務類型
• 競爭環境
• 收入份額估算 - 生物製藥 CDMO 市場進入者
• 收入份額分析 - 生物製藥 CDMO 市場進入者

成長機會

• 增長機會 1：在歐洲建立 CGT 製造和銷售能力
• 增長機會 2：改善和擴大亞洲的病毒載體製造能力
• 增長機會 3：活性生物治療產品（微生物組）的製造能力
• 增長機會 4：在生物製造中採用 AI 和數字孿生
• 增長機會 5：新療法的發現和臨床前服務
• 增長機會 6：專用於 CGT 的 PAT 服務

下一步

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and manufacturing and packaging services, into one integrated process (from drug development through manufacturing).

The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs-from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Market Segmentation by Product Type
• Market Segmentation by Cell Expression System Type
• Market Segmentation by Service Type
• Key Regional Competitors in the Bio-CDMO Market
• Growth Drivers
• Growth Restraints

Growth Environment-Bio-CDMO Market

• Biologics Pipeline Overview
• Bio-CDMO Business Model-Value Chain Expansion
• Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine
• Impact of Biosimilar Launches on CDMOs
• Key Emerging Trends in the Bio-CDMO Industry
• New Modalities Paving the Way for New Entrants
• New Modalities Paving Way for New Entrants
• Product Distribution of Marketed Biologics in 2022
• Distribution of Bioprocessing Technique-Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing
• Regional Distribution of Total Biomanufacturing Capacity

Growth Opportunity Analysis-Bio-CDMO Industry

• Key Growth Metrics for the Global Bio-CDMO Market
• Forecast Framework-Bio-CDMO Market Sizing
• Forecast Methodology-Bio-CDMO Market
• Forecast Assumptions and Considerations-Bio-CDMO Market
• Revenue Forecast-Global Bio-CDMO Market
• Revenue Forecast Analysis-Global Bio-CDMO Market
• Revenue Forecast by Product Type
• Revenue Forecast Analysis by Product Type
• Revenue Forecast by Cell Expression System Type
• Revenue Forecast Analysis for Mammalian Expression Systems
• Revenue Forecast Analysis for Microbial Expression Systems
• Revenue Forecast Analysis for Other Expression Systems
• Revenue Split by Service Type
• Competitive Environment
• Revenue Share Estimation-Top Bio-CDMO Market Participants
• Revenue Share Analysis-Top Bio-CDMO Market Participants

Growth Opportunity Universe

• Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe
• Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia
• Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities
• Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing
• Growth Opportunity 5: Discovery and Preclinical Services for New Modalities
• Growth Opportunity 6: Purpose-built PAT Services for CGT

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer